GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Increasing evidence indicates that obesity is highly associated with chronic kidney disease (CKD). GLP-1 receptor (GLP-1R) agonist has shown benefits on kidney diseases, but its direct role on kidney metabolism in obesity is still not clear. This study aims to investigate the protection and metabolic modulation role of liraglutide (Lira) on kidney of obesity. Rats were induced obese by high-fat diet (HFD), and renal function and metabolism changes were evaluated by metabolomic, biological and histological methods. HFD rats exhibited systemic metabolic disorders such as obesity, hyperlipidemia and impaired glucose tolerance, as well as renal histological and function damages, while Lira significantly ameliorated these adverse effects in HFD rats. Metabolomic data showed that Lira directly reduced renal lipids including fatty acid residues, cholesterol, phospholipids and triglycerides, and improved mitochondria metabolites such as succinate, citrate, taurine, fumarate and nicotinamide adenine dinucleotide (NAD+) in the kidney of HFD rats. Furthermore, we revealed that Lira inhibited renal lipid accumulation by coordinating lipogenic and lipolytic signals, and partly rescued renal mitochondria function via Sirt1/AMPK/PGC1α pathways in HFD rats. This study suggested that Lira alleviated HFD-induced kidney injury at least partly via directly restoring renal metabolism, thus GLP-1R agonist is a promising therapy for obesity-associated CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below.”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [71]
In the citing paper
“They minimize renal hypoxic-ischaemic damage as they regulate the mitochondrial activity of renal cells [40];”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Predictors of New-Onset Kidney Disease in a Community-Based Population
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.291.7.844 · Cited by 1,241
Novel insights of dietary polyphenols and obesity
Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H., Shastri, A., Su, R., Bapat, P., Kwun, I., & Shen, C.-L. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.001 · Cited by 896
Obesity and Risk of Type 2 Diabetes and Cardiovascular Disease in Children and Adolescents
Goran, M. I., Ball, G. D. C., & Cruz, M. L. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021442 · Cited by 735
Association between obesity and kidney disease: A systematic review and meta-analysis
Wang, Y., Chen, X., Song, Y., Caballero, B., & Cheskin, L. J. (2008) · Kidney International · doi:10.1038/sj.ki.5002586 · Cited by 687
Cited by
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Hesp, A. C., Schaub, J. A., Prasad, P. V., Vallon, V., Laverman, G. D., Bjornstad, P., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.041 · Cited by 202
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
“In high-fat diet rats (HFD), liraglutide restored kidney mitochondrial function counteracting the decline of biogenesis of genes encoding for proteins of mitochondrial respiration and increasing the uncoupling protein 2 levels [30].”
BackgroundObesity and chronic kidney disease: A current review
Nawaz, S., Chinnadurai, R., Al‐Chalabi, S., Evans, P., Kalra, P. A., Syed, A. A., & Sinha, S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.629 · Cited by 168
“iting renal lipid accumulation and rescued renal mitochondria function after inducing obesity in rats using a high fat diet.(146) These data are encouraging to consider GLP‐1 RAs in people with obesity and”
BackgroundKhan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Renal Lipid Metabolism and Lipotoxicity in Diabetes
Thongnak, L., Pongchaidecha, A., & Lungkaphin, A. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.11.004 · Cited by 141
Obesity‐related glomerulopathy: Current approaches and future perspectives
Martínez‐Montoro, J. I., Morales, E., Cornejo-Pareja, I. M., Tinahones, F. J., & Fernández‐García, J. C. (2022) · Obesity Reviews · doi:10.1111/obr.13450 · Cited by 145
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
Zhang, F., Wang, C., Wen, X., Chen, Y., Mao, R., Cui, D., Li, L., Liu, J., Chen, Y., Cheng, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15250 · Cited by 84
Self-citationCao, X., Wang, N., Yang, M. J., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146962 · Cited by 79
“Finerenone antagonizes the action of aldosterone, down-regulates inflammatory fibrosis genes such as TGF-β 1 and collagen 1A1, reduces water and sodium retention, and has excellent renal and cardiac protective effects in diabetic nephropathy [190].”
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Lg, S., Дігтяр, Н. І., Селіхова, Л. Г., Кайдашева, Е. І., Shlykova, O. A., Vesnina, L. E., & Кайдашев, І. П. (2019) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2019-0003 · Cited by 81
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Cimino, G., Vaduganathan, M., Lombardi, C., Pagnesi, M., Vizzardi, E., Tomasoni, D., Adamo, M., Metra, M., & Inciardi, R. M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14560 · Cited by 67
“112 This may be particularly important in HFpEF.”
BackgroundNephroprotective effects of GLP-1 receptor agonists: where do we stand?
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00738-9 · Cited by 56
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
“ulate the mitochondrial activity of renal cells [40]; • They prevent oxidative damage and the formation of oxygen”
Zeng, S., Wu, X., Chen, X., Xu, H., Zhang, T., & Xu, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2018.08.002 · Cited by 57
Wang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52
Ye, Y., Zhong, X., Li, N., & Pan, T. (2019) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2019.03.003 · Cited by 53
Natural antioxidants’ effects on endoplasmic reticulum stress-related diseases
Reyes-Fermín, L. M., Aparicio-Trejo, O. E., Avila-Rojas, S. H., Gómez-Sierra, T., Martínez-Klimova, E., & Pedraza-Chaverri, J. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111229 · Cited by 50
The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets
Takasu, M., Kishi, S., Nagasu, H., Kidokoro, K., Brooks, C. R., & Kashihara, N. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.035 · Cited by 55
“101,102 These fi ndings suggest that GLP-1RAs may directly or indirectly ameliorate mitochondrial damage.”
Xu, J., Wei, G., Wang, J., Zhu, J., Yu, M., Zeng, X., Wang, H., Xie, W., & Kong, H. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0170-0 · Cited by 49
Cruz‐Gregorio, A., Aranda‐Rivera, A. K., Aparicio‐Trejo, O. E., Coronado-Martínez, I., Pedraza‐Chaverrí, J., & Lizano, M. (2019) · Biomolecules · doi:10.3390/biom9080351 · Cited by 45
Khalifa, O., AL-Akl, N. S., Errafii, K., & Arredouani, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06143-5 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Self-citationWu, P., Dong, Y., Chen, J., Guan, T., Cao, B., Zhang, Y., Qi, Y., Guan, Z., & Wang, Y. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00460-9 · Cited by 46
“Previous studies have found that liraglutide can promote the mitochondrial function of dopamine neurons and kidney cells through the AMPK/PGC-1α signaling pathway (Ma et al. 2019; Wang et al. 2018).”
BackgroundA minireview: Role of AMP-activated protein kinase (AMPK) signaling in obesity-related renal injury
Zhuo, L., Li, J. X., Miao, X., Cui, W., Miao, L., & Cai, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118828 · Cited by 45
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 38
“The activation of this pro-inflammatory protein complex is induced by hyperglycemia and attenuates the therapeutic effects of the GLP-1R agonist by its downregulation [42].”
BackgroundReyes-Fermín, L. M., Avila-Rojas, S. H., Aparicio‐Trejo, O. E., Tapia, E., Rivero, I., & Pedraza‐Chaverrí, J. (2019) · Antioxidants · doi:10.3390/antiox8050133 · Cited by 36
The Mitochondrion: A Promising Target for Kidney Disease
Tanrıöver, C., Çöpür, S., Uçku, D., Cakir, A. B., Hasbal, N. B., Soler, M. J., & Kanbay, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020570 · Cited by 32
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Ali, M. M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. I. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 41
Chen, D., Wu, J., & Li, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055296 · Cited by 38
“receptor-γ coactlvator-1α (PGC-1α) pathways (Wang et al., 2018).”
Thongnak, L., Chatsudthipong, V., Kongkaew, A., & Lungkaphin, A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114997 · Cited by 29
The Impact of Incretin-Based Medications on Lipid Metabolism
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1815178 · Cited by 33
“Thus, incretin-based therapies could be promising agents for improving dyslipidemia and lipid homeostasis [73] by altering the balance between lipogenesis and lipolysis toward lower adiposity and prevention of diabetes-related dyslipidemia-induced complications such as diabetic nephropathy [74, 75] and beta cell dysfu…”
BackgroundThongnak, L., Chatsudthipong, V., & Lungkaphin, A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158755 · Cited by 28
Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications
Afşar, B., Hornum, M., Afşar, R. E., Ertuğlu, L. A., Ortíz, A., Covic, A. C., van Raalte, D. H., Cherney, D. Z. I., & Kanbay, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.016 · Cited by 30
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
“Insulin resistance in T2D leads to increased insulin secretion, growth factor release, and dysregulation of the glomerular filtration barrier, culminating in the obesity-related glomerulopathy and further kidney injury [106,107].”
BackgroundResultMechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Poledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 29
The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
García-Carro, C., Vergara, A., Agraz, I., Jacobs-Cachá, C., Espinel, E., Serón, D., & Soler, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060864 · Cited by 29
“In a high-fa -diet-induced obesity mice model with renal impairment, liraglutid treat ent likely protected subjects f om kidney injury through lipid and mitochondrial metabol sm regulation via the sirtuin/AMP-a tivated prot in kinase/peroxisome proliferator-activated receptor gamma coactivat r 1-alpha (S rt1/AMPK/PGC1…”
BackgroundD’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
Fatty kidney: A possible future for chronic kidney disease research
Kanbay, M., Çöpür, S., Demiray, A., Sag, A. A., Covic, A. C., Ortíz, A., & Tuttle, K. R. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13748 · Cited by 26
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below.”
Okuma, H., & Tsuchiya, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108699 · Cited by 24
Anti-obesity pharmacotherapy in adults with chronic kidney disease
Taber-Hight, E., Gilmore, A. C., & Friedman, A. N. (2023) · Kidney International · doi:10.1016/j.kint.2023.10.014 · Cited by 22
Liu, Q., Guo, S., Tong, Y., Li, Q., Baoxiang, Z., Wang, J., Wang, Y., Gao, W., & Zou, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70220 · Cited by 21
“194 Building on the preclinical foundation of GLP-1RAs-mediated protection against renal lipotoxicity, large-scale clinical trials have firmly established their broad renoprotective effects.”
Dekkers, I. A., Bizino, M. B., Paiman, E. H. M., Smit, J. W. A., Jazet, I. M., de Vries, A. P. J., & Lamb, H. J. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.09.006 · Cited by 21
Wahba, N. S., Abdel-Ghany, R. H., Ghareib, S. A., Abdel-Aal, M., & Alsemeh, A. E. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105196 · Cited by 20
Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
Okuma, H., Mori, K., Nakamura, S., Sekine, T., Ogawa, Y., & Tsuchiya, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147329 · Cited by 20
“SGLT2 inhibitors as in the present study, thiazolidinediones [24], DPP4 inhibitors [25], and GLP-1 agonists [26] reportedly attenuate albuminuria in obese or diabetic model mice.”
BackgroundObesity-Related Glomerulopathy: Clinical Management
Herman‐Edelstein, M., Weinstein, T., & Chagnac, A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.007 · Cited by 21
Li, K., Sun, J., Huang, N., Ma, Y., Han, F., Liu, Y., Hou, N., & Sun, X. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13391 · Cited by 18
Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects
Zaitoon, H., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01066-0 · Cited by 28
“Glucagon-like peptide-1 (GLP-1) has a renoprotective role in CKM syndrome by mobilizing fat out of the kidney, thus reducing lipotoxicity 88,108 and lowering inflammation, oxidative stress, mitochondrial dysfunction and insulin resistance in both podocytes and proximal tubular cells 109,110 .”
Sarker, M. K., Lee, J. H., Lee, D. H., Chun, K., & Jun, H. (2020) · Aging · doi:10.18632/aging.102643 · Cited by 20
Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
Chen, X., Chen, S., Ren, Q., Niu, S., Pan, X., Yue, L., Li, Z., Zhu, R., Jia, Z., Chen, X., et al. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s383537 · Cited by 17
“26,47,53 In our study, the levels of PLs and LysoPLs metabolites in the kidney of HFD group were significantly increased, indicating an imbalance of lipid metabolism in obese mice.”
Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment
Li, Q., Shang, J., & Inagi, R. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.12.029 · Cited by 17
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
“The efficacy and safety of ACE inhibitors and ARB in DKD patients are still controversial (Wang et al., 2018; He et al., 2020).”
BackgroundIliuta, I.-A., Song, X., Pickel, L., Haghighi, A., Retnakaran, R. R., Scholey, J. W., Sung, H., Steinberg, G. R., & Pei, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962933 · Cited by 14
“Furthermore, HFD can reduce the kidney expression of NRF1 and TFAM, thereby compromising mitochondrial biogenesis, in addition to inhibiting PGC-1α (Wang et al., 2018).”
BackgroundInfluentialMohamad, H. E., Abdelhady, M. A., Aal, S. M. A., & Elrashidy, R. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120999 · Cited by 14
RetractedLi, R., Li, W., Zhou, Y., Liao, G., Peng, G., Zhou, Y., Gou, L., Zhu, X., Hu, L., Zheng, X., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.036 · Cited by 14
Self-citationRenoprotective Effects of Incretin‐Based Therapy in Diabetes Mellitus
Yaribeygi, H., Atkin, S. L., Montecucco, F., Jamialahmadi, T., & Sahebkar, A. (2021) · BioMed Research International · doi:10.1155/2021/8163153 · Cited by 14
“These agents may provide further protection of the kidney by indirect and “pleiotropic” effects in addition to optimizing glycemic control [12].”
BackgroundLu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“Furthermore, GLP-1RAs show an antioxidant effect by lowering oxida - tive markers and improving oxidative damage, as reported by various investigations [200, 203, 206, 207].”
Chronic constant light exposure aggravates high fat diet-induced renal injury in rats
Lin, X., Wu, S., Shi, Y., Yue, F., Lin, W., Russell, R., & Zhang, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900392 · Cited by 13
“CD68 is regarded as a marker of macrophage infiltration (27).”
BackgroundAnumas, S., & Inagi, R. (2025) · Nephrology · doi:10.1111/nep.70098 · Cited by 12
“In obese rats, liraglutide alleviated HFD-induced renal injury by decreasing renal lipid accumulation, modulating lipogenic and lipolytic pathways, and restoring mitochondrial function via the Sirt1/AMPK/PGC1α signalling axis [122].”
Galectins as potential pharmacological targets in renal injuries of diverse etiology
Gu, M., Mei, X., & Zhao, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173213 · Cited by 12
Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2537446 · Cited by 9
“Preclinical studies suggest GLP-1RAs help restore kidney metabolic balance and vascular tissue by reducing lipid and fat accumulation [136,137], improving ATP production, lowering inflammation, and decreasing oxidative stress [138,139].”
Hsiao, C.-C., Chen, M., Liu, C. Y., Chan, C.-Y., Fang, Y.-W., Liou, H., & Tsai, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf172 · Cited by 11
Contreras, C., Muñoz, M., Freire-Agulleiro, Ó., Estévez, Á., Martínez, M. P., Olmos, L., del Val, A. G., Rodríguez, C., Silvestre, R. A., Sánchez, A., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103760 · Cited by 10
“…include glomerular endothelium from HFD-induced obese rats, consistent with the dysregulation of PGC-1 α reported in obese patients and animals [58 – 60], and with the lower gene expression of PGC-1 α associated to impaired biogenesis and reduced mitochondrial complex activity reported for the…”
Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy
Stelmaszyk, A., Mikołajczak, P. Ł., & Dworacka, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174289 · Cited by 10
Management of Diabetic Nephropathy: The Role of Sirtuin-1
Wang, W., Sun, W., Cheng, Y., Xu, Z., & Cai, L. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0153 · Cited by 10
Thongnak, L., Pengrattanachot, N., Promsan, S., Phengpol, N., Sutthasupha, P., Jaikumkao, K., & Lungkaphin, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01439-0 · Cited by 8
Liu, J., Sun, Y., Zheng, H., Wang, J., Liu, L., Song, B., & Zhang, H. (2021) · BioMed Research International · doi:10.1155/2021/6662704 · Cited by 9
“This is consistent with previous research [21].”
BackgroundSelf-citationImmune-mediated interactions between sarcopenia and atherosclerosis in aging
Yu, M., Zhao, R., Ge, L.-C., Yu, T., Shen, H., Dai, C., & Wang, H. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00537-5 · Cited by 9
“Combination therapies with GLP-1 receptor agonists may counter metabolic dysregulation and exert anti-inflammatory effects via Sirt1/AMPK/PGC1α activation [160, 161].”
Luetić, M., Kretzschmar, G., Grobe, M., Jerčić, L., Bota, I., Ivić, V., Balog, M., Zjalić, M., Uljević, M. V., Heffer, M., et al. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151817 · Cited by 6
Blockbuster Medications for Obesity: A Primer for Nephrologists
Zeitler, E. M., Dabb, K., Nadeem, D., Still, C. D., & Chang, A. R. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.009 · Cited by 6
Impact of CVOTs in primary and secondary prevention of kidney disease
Cosmo, S. D., Viazzi, F. C., Piscitelli, P. A., Leoncini, G., Mirijello, A., Bonino, B., & Pontremoli, R. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107907 · Cited by 7
Garavaglia, C., Ossoli, A., & Gomaraschi, M. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02654-0 · Cited by 5
Tommerdahl, K. L., Kula, A. J., & Bjornstad, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2203319 · Cited by 6
“Treatment with GLP-1RAs in obese rat models has resulted in restoration of kidney energy homeostasis, as well as a reduction in reactive oxygen species, inflammation, and fatty kidney [73].”
BackgroundEmerging insights into the role of visceral adipose tissue in diabetic kidney disease
Li, L., Liu, C., & Gu, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1715701 · Cited by 4
Self-citationMetabolomics for Preclinical Detection of Diabetic Kidney Disease: A Comprehensive Review
Garoufis, M., Sakkou, S. F., Kostara, C. E., Bairaktari, E. T., & Tsimihodimos, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020998 · Cited by 6
“By reversing hemodynamic overload and restoring metabolic homeostasis, these agents have been shown to preserve mitochondrial integrity and mitigate the bioenergetic burden on the diabetic kidney [28,29].”
Han, L., Chen, X., Wan, D.-W., Xie, M., & Ouyang, S. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02516-4 · Cited by 4
“Mechanically, liraglutide activates renal Sirt1/AMPK/PGC1α signaling pathway in high-fat-diet-induced obese rats [34].”
InfluentialRole of Deoxyribonucleic Acid Origami for Alleviating Kidney and Liver Injury in Diabetic Sepsis
Luo, X., Dai, W., Lin, T., Li, L., & Zhang, Y. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00543 · Cited by 4
Self-citationPlant-Based Diet Mitigated the Risk of Chronic Kidney Disease in Overweight Individuals
Hou, Y., Tseng, K.-H., Tzeng, I., Tsai, W., Liu, H.-W., Liu, J., Kuo, K.-C., Lai, Y.-C., Lu, K., Lin, I.-H., et al. (2025) · Annals of Nutrition and Metabolism · doi:10.1159/000545953 · Cited by 4
“Therapeutic strategies for obesity/overweight, such as bariatric surgery or glucagon-like peptide (GLP)-1 agonists, may alleviate CKD development [8, 9].”
Self-citationG protein-coupled receptor-mediated renal fibrosis: a key focus on kidney disease drug development
Wang, H., Yang, M., Liu, X., Fan, J., & Wang, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1645888 · Cited by 7
Self-citationZhong, Q., Zhang, Y., Sun, D., Peng, J., Zhang, P., Wang, R., Cao, L., Chen, H., Wu, C., & He, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788998 · Cited by 3
Hamilton, A., Thisted, L., Ougaard, M., Hahn, M., Andersen, K., Perens, J., Augustin, R., Bajrami, B., Rist, W., Christensen, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71387 · Cited by 3
Characterizing the metabolic response of the zebrafish kidney to overfeeding
Zeitler, E. M., Li, Y., Schroder, M., Falk, R. J., & Sumner, S. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00113.2023 · Cited by 3
Clinical characteristics and treatment compounds of obesity-related kidney injury
Mao, T., Huang, H.-Q., & Zhang, C.-H. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1091 · Cited by 4
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
“In experimental studies, GLP-1Rs improved renal vascularization and oxygen supply, lowering oxygen consumption and enhancing ATP production [68].”
Potential Therapeutic Targets of Obesity-Related Glomerulopathy
He, J., Xiao, Y., & Wang, J. (2021) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0141 · Cited by 2
“38 Farnesoid X-Activated Receptor Agonists Farnesoid X receptor (FXR) is a nuclear bile acid (BA) receptor and is activated by primary BAs such as cheno-deoxycholic acid (CDCA), cholic acid, and synthetic agonists such as obeticholic acid.”
Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
van Baar, M. J. B., & van Raalte, D. H. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000559 · Cited by 2
Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity
Rodrigo, N., Chen, H., Pollock, C. A., & Glastras, S. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-68234-9 · Cited by 1
“Interestingly, metabolomic studies using liraglutide show reduced renal lipids, including fatty acid residues, cholesterol, and TAG, with improvements in mitochondria metabolites such as succinate, citrate and taurine, rebalancing renal metabolism in obesity related kidney disease 56 .”
BackgroundSemaglutide’s Impact on Kidney Health in Obese Mice: A Metabolomics Study
Eriksson, J., & Lindgren, M. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/5whbt71l9k · Cited by 1
Mitochondrial Alterations and CKD: A Review
Pinzón-Cortés, J. A., Narongkiatikhun, P., Yuan, L., Meister, J., Hampson, H., van Raalte, D. H., Blondin, D. P., Capozzi, M. E., Sweet, I. R., Nelson, R. G., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.01.021 · Cited by 2
El-Kader, A. E.-K. M. A., Awadalla, E. A., Abdelsadik, A., & Seifeldin, E. A. (2021) · Aswan University Journal of Environmental Studies · doi:10.21608/aujes.2021.96449.1042 · Cited by 1
“Page 276 Abd El-Kader et al., 2021 Wang et al. (2018) showed obvious renal histological lesions including tubular hypertrophy, basement membrane thickening, mesangial expansion and glomerulosclerosis in addition to sustained inflammation and cell apoptosis in the kidney of HFD-group compared to…”
ResultAdvances in the Study of Obesity and Diabetic Vascular Complications
南, 汶. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133672
Metabolic Imaging: Measuring Fat in the Kidney
Dekkers, I. A., & Lamb, H. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-40169-5_14
GLP-1-receptoragonisták szerepe a krónikus vesebetegségben
Sztanek, F., Tóth, L., & Hernyák, M. (2024) · Diabetologia Hungarica · doi:10.24121/dh.2024.3
Bastawy, N., El‐Mosallamy, A. E. M. K., Rasheed, R. A., Sadek, A. S., Khattab, R. T., Ali, E. M., Zaghloul, R. A., Ghaly, W. B. A., & Boushra, A. F. (2025) · Hypertension Research · doi:10.1038/s41440-025-02403-9 · Cited by 1
“…activity in renal tissues by many interconnected pathways, such as direct transcriptional augmentation through the cAMP – PKA pathway [14], mitochondrial integrity enhancement via boosting Sirt1, p-AMPK, and PGC-1 α [15] and mediation of anti ‑ in-fl ammatory and anti fi brotic gene programs [16].”
Lai, W., Peng, L., Min, J., Qiu, L., Wang, C., Yu, S., Li, Q., Li, R., Jiang, X., & Chen, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665860
“It is reported that, in rat CKD models, the GLP-1R agonist Liraglutide could improve the mitochondrial function of renal cells by activating the SIRT1/AMPK/PGC1 a pathway, and reduce lipid accumulation in the kidney (43).”
Self-citation
Metadata
- Authors
- Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Lu, Yanrong
- Liu, Jingping
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-03-28
- Volume
- 13
- Issue
- 3
- Pages
- e0193473
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5873987
- OpenAlex
- W2795005430
- Cited by
- 110
- References
- 48
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 13 · 2023: 12 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 12 · 2018: 1
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (31200754, 81571808)
- China Postdoctoral Science Foundation (2012M511931)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, liraglutide, obesity, chronic kidney disease, renal metabolism, high-fat diet, renal lipid accumulation, mitochondrial function, hyperlipidemia, impaired glucose tolerance
- MeSH terms
- Liraglutide, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Fibrosis, Homeostasis, Kidney, Male, Mitochondria, Obesity, Signal Transduction, Rats, Sprague-Dawley, Lipid Metabolism, Rats, AMP-Activated Protein Kinases, Metabolomics, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.